🧾 What This Document Is

This is a press release (filed as a 6-K form) announcing that the company, Evaxion, will be presenting new research at a major scientific conference. It’s a way for the company to share exciting news with the public and investors.

🏢 What The Company Does

👉 In simple terms, Evaxion is a biotech company that uses artificial intelligence as a tool to design new vaccines. Their platform, called AI-Immunology™, acts like a super-powered decoder ring to understand the human immune system and find the best targets for vaccines against cancer and infectious diseases.

🔬 The New Polio Vaccine Concept

The big news here is that Evaxion used its AI platform to create brand-new ideas for a next-generation polio vaccine.

• The Goal: Current polio vaccines work but have some weaknesses. The aim is to design a new vaccine that combines the best features of the old ones to finally wipe out polio for good.
• The AI Approach: Evaxion’s AI didn’t just tweak old designs; it proposed fundamentally new ones. These include "hybrid capsid designs" and "de novo designed B-cell antigen approaches." In layman's terms, they're engineering new protective shells and key immune system targets from the ground up.
• The Partner: This research was done in collaboration with the Gates Foundation, a major player in global health.

👉 Why it matters: Polio isn't gone yet. This shows AI can tackle old, persistent diseases in ways decades of traditional research hasn't fully solved.

💻 The CMV Vaccine Program Update

Evaxion will also present data on another project: EVX-V1, a vaccine targeting Cytomegalovirus (CMV). Their AI helped discover novel CMV antigens (the parts the immune system learns to recognize). They are mixing these new, AI-discovered targets with optimized versions of known targets to create a stronger, multi-pronged vaccine.

📅 Presentation Schedule

The company will present this research at the World Vaccine Congress in Washington D.C.:

• Polio Vaccine: April 1, 2026, at 16:40 ET. Presenter: Thomas Trolle, PhD, Director, Bioinformatics.
• CMV Vaccine: April 2, 2026, at 10:25 ET. Presenter: Pär Comstedt, VP, Infectious disease vaccine development.

⚖️ Big Picture: Strengths & Risks

• 👍 Strengths: Validates their AI platform in a new disease area (polio). High-profile collaboration with the Gates Foundation boosts credibility. Shows progress in key pipeline programs.
• ⚠️ Risks: These are still "design concepts" and early-stage research. Turning concepts into real, approved vaccines takes many years and significant funding. The success of any AI-discovered vaccine candidate is not guaranteed.

🧠 The Analogy

Using AI to design a new vaccine is like using a GPS and terrain-mapping software to plan a hike through a vast, complex mountain range (the human immune system) that scientists have been exploring on foot for decades. Evaxion's software is identifying new, potentially better routes to the summit that weren't visible before.

📇 Key Contacts & People

• Mads Kronborg: Vice President, Investor Relations & Communication
• Phone: +45 53 54 82 96
• Email: [email protected]
• Presenters: Thomas Trolle, PhD (Director, Bioinformatics) and Pär Comstedt (VP, Infectious disease vaccine development)

🧩 Final Takeaway

Evaxion is using its AI platform to cook up new vaccine recipes for old diseases like polio, partnering with the Gates Foundation and presenting the promising early concepts to the scientific community. This is a showcase of their technology's potential.